Tuesday, September 12, 2017 5:48:35 PM
Advanced CGM Technology with Extended Long-Term Wear of up to 180 Days
Business Wire
GERMANTOWN, Md. -- September 12, 2017
Senseonics Holdings, Inc. (NYSE-MKT-SENS) today announced it has received CE Mark approval for the Eversense® XL Continuous Glucose Monitoring (CGM) System. The Eversense XL System includes an extended life implanted glucose sensor lasting up to 180 days, a removable discreet smart transmitter, and a mobile app for display of real-time glucose readings. The Eversense XL System provides the world’s longest-lasting sensor, compared to the frequent weekly sensor insertions required by other CGM systems.
"We are pleased to announce the CE Mark approval of the Eversense XL System, representing another significant milestone for Senseonics. When we introduced the Eversense System last year, we were providing the longest-wear sensor with up to 90-day wear for people with diabetes. Now with the new Eversense XL System’s even longer sensor duration, patients can extend a single sensor wear over 3 seasons – inserting a new sensor in the Fall which will continue through the Winter to be replaced in Spring,” said Tim Goodnow, CEO and President of Senseonics. “As we continue to advance our product portfolio with extended long-term sensor capabilities, we are offering added convenience to support patients’ continuous glucose management. We are excited to bring this product to market in Europe in the fourth quarter of 2017.”
CE Mark indicates that the product design conforms to the requirements of the Active Implantable Medical Device Directive (AIMDD 90/385/EEC). Eversense XL is indicated for continually measuring interstitial fluid glucose levels in adults and to be used as an adjunctive device to complement information obtained from standard home blood glucose meters.
“We are all aware of the advantages of continuous glucose monitoring seen now in many studies, including improvements in glycemic control, quality of life and reduction in hypoglycemia,” said Dr. Pratik Choudhary, Senior Lecturer and Consultant in Diabetes at King’s College London. “The benefits have been linked with long-term usage, which for many requires changing sensors every week. Eversense now offers a unique option for people who want to use CGM long term, with a long-lasting sensor that has demonstrated accuracy.”
Eversense XL - advanced CGM technology with best in class sensor wear time for people with diabetes #ExtendedLifeCGM #EversenseCGM #AdvancedCGMTechnology
Recent SENS News
- Senseonics Holdings, Inc. to Participate in Upcoming Conferences • Business Wire • 05/02/2024 12:05:00 PM
- Senseonics Holdings, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 13, 2024 at 4:30 P.M. Eastern Time • Business Wire • 04/30/2024 08:05:00 PM
- Eversense® CGM System Receives iCGM Designation by the US FDA • Business Wire • 04/30/2024 11:00:00 AM
- SAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS • PR Newswire (US) • 03/12/2024 11:00:00 AM
- Senseonics Holdings, Inc. Announces Data From the Eversense® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes • Business Wire • 03/08/2024 01:05:00 PM
- Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference • Business Wire • 03/06/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:12:59 PM
- Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 02/29/2024 09:05:00 PM
- Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 29, 2024 at 4:30 P.M. Eastern Time • Business Wire • 02/15/2024 09:05:00 PM
- Medicare Coverage Significantly Expanded for the Eversense E3 CGM System • Business Wire • 02/12/2024 12:00:00 PM
- MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM • PR Newswire (US) • 02/12/2024 12:00:00 PM
- PHC Holdings Corporation and Senseonics Announce Appointment of Brian Hansen as President of CGM at Ascensia Diabetes Care • Business Wire • 02/06/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:49:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:48:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:48:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:47:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:36:51 PM
- Senseonics Holdings, Inc. Announces Business Updates • Business Wire • 01/02/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 09:57:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 09:56:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 09:54:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 09:53:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:27:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:14:22 PM
- Senseonics Holdings, Inc. Reports Third Quarter 2023 Financial Results • Business Wire • 11/09/2023 09:05:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM